A detailed history of Pathstone Holdings, LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Pathstone Holdings, LLC holds 10,871 shares of EXAS stock, worth $609,971. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,871
Previous 7,163 51.77%
Holding current value
$609,971
Previous $302,000 145.03%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$42.43 - $70.83 $157,330 - $262,637
3,708 Added 51.77%
10,871 $740,000
Q2 2024

Aug 14, 2024

SELL
$41.33 - $74.26 $120,600 - $216,690
-2,918 Reduced 28.95%
7,163 $302,000
Q1 2024

May 13, 2024

BUY
$56.27 - $73.77 $95,040 - $124,597
1,689 Added 20.13%
10,081 $696,000
Q4 2023

Feb 14, 2024

BUY
$59.06 - $75.72 $495,631 - $635,442
8,392 New
8,392 $620,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $9.93B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Pathstone Holdings, LLC Portfolio

Follow Pathstone Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Holdings, LLC with notifications on news.